At the news
? NEUTRALIMPACT 3/10 8-K filed May 22, 2026 at 09:03 ET
Oncolytics announced translational data from the GOBLET and AWARE-1 trials to be presented at ASCO 2026, showing pelareorep activates innate and adaptive immune responses and expands mutant KRAS-specific T cells. The press release contains no new financial information or definitive clinical outcomes, making this a routine scientific update.
- Data will be presented at ASCO 2026 (May 29-June 2) on pelareorep's mechanism of action.
- Translational analyses show pelareorep induces antiviral and anti-tumor immune responses.
- Expansion of mutant KRAS-specific T cell clones correlated with tumor volume reduction in pancreatic cancer.
- AWARE-1 breast cancer biopsies showed increased CXCL13 and tertiary lymphoid structure formation.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access